Total submissions: 8
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Evidence- |
RCV000111934 | SCV000299830 | pathogenic | Breast-ovarian cancer, familial, susceptibility to, 1 | 2016-09-08 | reviewed by expert panel | curation | Variant allele predicted to encode a truncated non-functional protein. |
Ambry Genetics | RCV000165693 | SCV000216432 | pathogenic | Hereditary cancer-predisposing syndrome | 2014-08-29 | criteria provided, single submitter | clinical testing | The c.2762delA pathogenic mutation (also known as 2881delA), located in coding exon 9 of the BRCA1 gene, results from a deletion of one nucleotide at nucleotide position 2762, causing a translational frameshift with a predicted alternate stop codon. This alteration has been reported in multiple breast and/or ovarian cancer families of Czech ancestry (Machackova E, BMC Cancer 2008 ; 8:140). In addition to the clinical data presented in the literature, since frameshifts are typically deleterious in nature, this alteration is interpreted as a disease-causing mutation (ACMG Recommendations for Standards for Interpretation and Reporting of Sequence Variations. Revision 2007. Genet Med. 2008;10:294). |
Consortium of Investigators of Modifiers of BRCA1/2 |
RCV000111934 | SCV000325458 | pathogenic | Breast-ovarian cancer, familial, susceptibility to, 1 | 2015-10-02 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000657211 | SCV000778937 | pathogenic | not provided | 2022-03-17 | criteria provided, single submitter | clinical testing | Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Observed in individuals with a personal or family history consistent with pathogenic variants in this gene (Foretova 2004, Machackova 2008); Not observed at significant frequency in large population cohorts (gnomAD); Truncating variants in this gene are considered pathogenic by a well-established clinical consortium and/or database; Also known as 2881delA; This variant is associated with the following publications: (PMID: 18489799, 15024741, 32295079, 29446198, 31409081, 20104584, 32438681) |
Labcorp Genetics |
RCV001383398 | SCV001582531 | pathogenic | Hereditary breast ovarian cancer syndrome | 2023-01-01 | criteria provided, single submitter | clinical testing | This premature translational stop signal has been observed in individual(s) with hereditary breast and ovarian cancer (PMID: 15024741, 18489799, 29446198). This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Gln921Argfs*79) in the BRCA1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in BRCA1 are known to be pathogenic (PMID: 20104584). ClinVar contains an entry for this variant (Variation ID: 54674). For these reasons, this variant has been classified as Pathogenic. |
Color Diagnostics, |
RCV000165693 | SCV004360255 | pathogenic | Hereditary cancer-predisposing syndrome | 2021-10-25 | criteria provided, single submitter | clinical testing | This variant deletes 1 nucleotide in exon 10 of the BRCA1 gene, creating a frameshift and premature translation stop signal. This variant is expected to result in an absent or non-functional protein product. This variant has been reported in at least one individual and a family affected with breast or ovarian cancer and has been identified in a family among the CIMBA participants (PMID: 15024741, 18489799, 29446198). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Loss of BRCA1 function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic. |
Breast Cancer Information Core |
RCV000111934 | SCV000144538 | pathogenic | Breast-ovarian cancer, familial, susceptibility to, 1 | 2005-07-20 | no assertion criteria provided | clinical testing | |
CZECANCA consortium | RCV001271010 | SCV001451822 | pathogenic | Breast and/or ovarian cancer | 2019-06-11 | no assertion criteria provided | clinical testing |